Download the app
App StorePlay Store
Beige
Login
← All tags

glp-1

Dr Reddy’s launches generic Semaglutide in Canada first G7 approval could widen GLP-1 access fast

Dr Reddy’s launches generic Semaglutide in Canada first G7 approval could widen GLP-1 access fast

Dr Reddy’s Laboratories has launched a generic Semaglutide injection in Canada for adults with type 2 diabetes, following Health Canada approval granted on April 28, 2026. The move makes Canada the first G7 nation to authorize Semaglutide, positioning the company among the earliest generics entrants in that market. The launch follows Dr Reddy’s recent introduction in India under the brand name Obeda. Supplied as a sterile prefilled pen, it is offered in 2 mg and 4 mg strengths.

Summarised by Beize from a story on The Economic Times on 16 May 2026
Agilent and Veeda Launch Bengaluru Center of Excellence for GLP 1 Analytics Ready for Inspections

Agilent and Veeda Launch Bengaluru Center of Excellence for GLP 1 Analytics Ready for Inspections

Agilent Technologies is partnering with Veeda Lifesciences to launch a joint Center of Excellence in Bengaluru focused on regulatory-aligned analytical and bioanalytical workflows. The hub aims to produce consistent, inspection-ready data across early development, clinical and manufacturing stages, with special emphasis on GLP-1 peptides where sensitivity, throughput and data integrity are crucial. The collaboration combines Agilent mass spectrometry with Veeda proteomics and impurity analysis capabilities.

Summarised by Beize from a story on IndianWeb2 on 13 May 2026

Your news, in seconds

App StorePlay Store
Torrent wins 38 percent share as semaglutide generics surge across India

Torrent wins 38 percent share as semaglutide generics surge across India

After Novo Nordisk’s innovator semaglutide patent expired in end-March, over a dozen Indian firms launched generics. In April, these generics sold about ₹44 crore in total, with Torrent emerging as the fastest mover, grabbing around 38% market share. The sprint signals intensifying competition in GLP-1 diabetes and weight-management drugs.

Summarised by Beize from a story on The Economic Times on 7 May 2026
Emcure ramps up R and D and bets on global acquisitions for next wave of growth

Emcure ramps up R and D and bets on global acquisitions for next wave of growth

Emcure Pharmaceuticals is accelerating domestic expansion while scaling R&D and manufacturing capacity. The company is also scouting acquisition opportunities both in India and abroad, aiming to add new products to fuel growth. A key driver is its partnership with Novo Nordisk for GLP-1 therapies, alongside a pipeline of complex injectables poised to support momentum ahead.

Summarised by Beize from a story on The Economic Times on 6 May 2026
RPG Life Sciences to scale API business and target GLP 1 entry by August September

RPG Life Sciences to scale API business and target GLP 1 entry by August September

RPG Life Sciences says it is doubling down on its API business as the growth engine, while lining up a significant acquisition to expand capacity. The company also plans to enter the GLP-1 weight-loss therapy market by August-September, despite geopolitical risks. Its strategy centers on niche, complex molecules and moving into new therapy areas.

Summarised by Beize from a story on The Economic Times on 30 Apr 2026
Eli Lilly lifts forecasts as oral GLP 1 pill and Zepbound drive results

Eli Lilly lifts forecasts as oral GLP 1 pill and Zepbound drive results

Eli Lilly raised its annual profit and revenue outlook after a stronger-than-expected first quarter, powered by steady demand for its GLP-1 therapies. Results followed the company’s initial reporting since launching its oral GLP-1 pill, Foundayo, with continued momentum for weight-loss and diabetes brands Zepbound and Mounjaro.

Summarised by Beize from a story on The Economic Times on 30 Apr 2026

Never miss a story

App StorePlay Store
GLP 1 weight loss drugs may reduce alcohol binges by half in new trial

GLP 1 weight loss drugs may reduce alcohol binges by half in new trial

A new trial suggests GLP-1 weight-loss drugs such as semaglutide could also curb heavy alcohol use. Researchers report weekly injections halved heavy drinking days among adults with alcohol use disorder. Because the same medicine is already used for obesity, the findings could translate into a new treatment pathway for millions, pending further research.

Summarised by Beize from a story on The Economic Times on 29 Apr 2026
Semaglutide API prices tumble as GLP-1 demand surges and generics flood markets

Semaglutide API prices tumble as GLP-1 demand surges and generics flood markets

Semaglutide API prices are falling sharply as global demand for weight-loss drugs like Ozempic and Wegovy drives rapid manufacturing expansion. With patents set to expire in key markets and Indian companies rolling out lower-priced generics, analysts expect additional price softening. The shift could widen access to these GLP-1 therapies for patients in the months ahead.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Eli Lilly responds after Gurugram bust of counterfeit Mounjaro made from China supplies

Eli Lilly responds after Gurugram bust of counterfeit Mounjaro made from China supplies

Gurugram law enforcement has reportedly dismantled a counterfeit Mounjaro operation, placing two people in custody. Authorities say the ring imported raw materials from China and manufactured the injections at a private home, supplying illicit diabetes and obesity drugs. Eli Lilly issued a statement after the Gurugram drug racket was exposed, underscoring growing concerns about counterfeit GLP-1 medications.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play